Skip to content

Study on the innovative pathogenesis of hypertensive heart failure and its clinical identification and treatment scheme Clinical study on the intervention of Qishen Granules Hypertension optimization formula (QSGOF)in hypertensive heart failure

Study on the innovative pathogenesis of hypertensive heart failure and its clinical identification and treatment scheme Clinical study on the intervention of Qishen Granules Hypertension optimization formula (QSGOF)in hypertensive heart failure

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000665
Enrollment
Unknown
Registered
2025-04-06
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive heart failure

Interventions

Test Group:Qishen Granules Hypertension optimization formula (QSGOF)
Control Group: Qishen Granules Hypertension optimization formula (QSGOF) placebo

Sponsors

Guang'anmen Hospital China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Meet the diagnostic criteria of hypertension and chronic heart failure and fulfill the criteria of left ventricular ejection fraction (LVEF) =40% and serum NT-proBNP level =450pg/ml; (2) Meet the criteria for the evidence of Toxic Evil Evidence of Heart Failure in Chinese medicine; 3)Age 18-75 years old gender is not limited; 4) NYHA class II-III; 5)Voluntary participation understanding and signing the informed consent.

Exclusion criteria

Exclusion criteria: 1) Acute stage of myocardial infarction (within 14 days); 2) Combined severe hepatic insufficiency (ALT>100U/L or AST>100U/L) severe renal insufficiency (glomerular filtration rate 5.5mmol/L or <3.5mmol/L); 3) Severe hematologic disease or malignancy; 4) Pregnancy or lactation; 5) Psychiatric patients; 6) Those with severe heart failure and life expectancy of less than six months; 7) Those who have taken Chinese medicine or proprietary Chinese medicine with similar function or components to the test drug within the last month; 8) Those who are known to have adverse reaction or allergy to the study drug; 9) those who participated in other drug clinical studies within 1 month before enrollment.

Design outcomes

Primary

MeasureTime frame
Efficacy of treatment (defined as a reduction in NT-proBNP of more than 30%);Six-minute walk experiment;

Secondary

MeasureTime frame
Heart Failure Toxic Evidence Quantification Scale;Quantification of Heart Failure Symptom Grading Scale;Kansas City Quality of Life Scale for Cardiomyopathy Patients;Echocardiography-related indicators;NYHA Cardiac Function Classification;

Countries

China

Contacts

Public ContactJun Li

Guang'anmen Hospital China Academy of Chinese Medical Sciences

gamyylj@163.com13051458913

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Sep 9, 2026